Product Description
Brenipatide (GIP/GLP-1 Coagonist III) is a biologic entity being studied for the treatment of cardiometabolic-related diseases. (Sourced from: https://www.lilly.com/science/research-development/pipeline)
Mechanisms of Action: GIP Agonist, GLP-1 Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Hungary, India, Japan, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 26
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Alcoholism|Depressive Disorder, Major
Phase 2: Asthma|Bipolar Disorder|Constipation|Diarrhea|Irritable Bowel Syndrome|Opioid-Related Disorders|Schizophrenia|Tobacco Use Disorder
Phase 1: Healthy Volunteers|Hepatic Insufficiency|Kidney Failure, Chronic|Obesity|Overweight
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07219173 |
J2S-MC-GZMR | P2 |
Recruiting |
Asthma |
2028-04-01 |
12% |
2025-10-28 |
|
NCT07420283 |
RENEW-Op-1 | P2 |
Recruiting |
Opioid-Related Disorders |
2028-03-01 |
12% |
2026-04-24 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT07410507 |
RENEW-Scz-1 | P2 |
Recruiting |
Schizophrenia |
2027-11-01 |
12% |
2026-03-26 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07219953 |
RENEW-ALC-2 | P3 |
Recruiting |
Alcoholism |
2028-04-01 |
50% |
2025-11-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07412756 |
RENEW-MDD-1 | P3 |
Recruiting |
Depressive Disorder, Major |
2028-02-01 |
49% |
2026-03-24 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07286175 |
RENEW-Bipolar-1 | P2 |
Recruiting |
Bipolar Disorder |
2027-11-01 |
12% |
2025-12-17 |
Primary Endpoints|Treatments |
NCT07545759 |
RENEW-IBS-D | P2 |
Recruiting |
Irritable Bowel Syndrome|Diarrhea |
2027-09-01 |
12% |
2026-05-14 |
|
NCT07545772 |
RENEW-IBS-C | P2 |
Recruiting |
Irritable Bowel Syndrome|Constipation |
2027-07-01 |
12% |
2026-05-14 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07223840 |
RENEW-Smk-1 | P2 |
Recruiting |
Tobacco Use Disorder |
2027-02-01 |
12% |
2025-11-25 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT07165015 |
J2S-MC-GZMM | P1 |
Completed |
Kidney Failure, Chronic |
2026-04-16 |
50% |
2026-04-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06606106 |
J2S-MC-GZMD | P1 |
Active, not recruiting |
Obesity|Overweight |
2026-07-01 |
88% |
2026-01-21 |
|
NCT07165002 |
J2S-MC-GZML | P1 |
Recruiting |
Hepatic Insufficiency |
2026-08-01 |
50% |
2025-11-19 |
Primary Endpoints|Start Date|Treatments|Trial Status |
jRCT2021250055 |
jRCT2021250055 | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2028-02-29 |
|||
2025-522308-25-00 |
J2S-MC-GZMH | P3 |
Not yet recruiting |
Depressive Disorder, Major |
2028-02-06 |
49% |
||
NCT07476118 |
J2S-MC-GZMU | P1 |
Recruiting |
Overweight|Obesity |
2027-02-01 |
88% |
2026-04-23 |
|
jRCT2071250095 |
jRCT2071250095 | P2 |
Not yet recruiting |
Asthma |
2028-10-16 |
|||
2025-522640-41-00 |
J2S-MC-GZMR | P2 |
Not yet recruiting |
Asthma |
2028-06-16 |
|||
jRCT2021250043 |
jRCT2021250043 | P2 |
Not yet recruiting |
Bipolar Disorder |
2028-03-31 |
|||
jRCT2021250053 |
jRCT2021250053 | P2 |
Not yet recruiting |
Schizophrenia |
2027-12-31 |
|||
jRCT2031250568 |
jRCT2031250568 | P2 |
Not yet recruiting |
Tobacco Use Disorder |
2027-05-01 |
|||
2025-522312-16-00 |
J2S-MC-GZMP | P3 |
Not yet recruiting |
Alcoholism |
2028-04-01 |
50% |
||
NCT07219966 |
RENEW-ALC-1 | P3 |
Recruiting |
Alcoholism |
2028-04-01 |
50% |
2025-12-05 |
Primary Endpoints|Start Date|Treatments|Trial Status |
2025-522313-38-00 |
J2S-MC-GZME | P3 |
Not yet recruiting |
Alcoholism |
2028-04-01 |
50% |
||
jRCT2071250111 |
jRCT2071250111 | P3 |
Not yet recruiting |
Alcoholism |
2028-03-31 |
|||
jRCT2071250110 |
jRCT2071250110 | P3 |
Not yet recruiting |
Alcoholism |
2028-03-31 |
Recent News Events
Date |
Type |
Title |
|---|